# Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

> **NCT07059494** · PHASE4 · RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **RADIATION:** Y^90 Radioembolization

## Key facts

- **NCT ID:** NCT07059494
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059494, "Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07059494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*